摘要
目的:探讨孟鲁司特对哮喘儿童血清金属蛋白酶-9(MMP-9)及其抑制剂-1(TIMP-1)水平的影响及疗效观察。方法:将80例急性发作期哮喘患儿随机分为孟鲁司特组40例和对照组40例。两组患儿均予以相同的抗感染、解痉平喘及止咳化痰等治疗,孟鲁司特组在此基础上加用孟鲁司特咀嚼片5 mg睡前口服,每天1次,连用12周。结果:治疗12周后,两组患儿血清MMP-9和MMP-9与TIMP-1比值较治疗前明显下降、TIMP-1水平明显上升(P<0.05),治疗后孟鲁司特组血清MMP-9、MMP-9与TIMP-1比值下降和TIMP-1水平上升程度与对照组比较差异有统计学意义(P均<0.05)。孟鲁司特组临床总有效率明显高于对照组(χ2=4.11,P<0.05),两组患儿治疗期间均未发现明显药物不良反应。结论:孟鲁司特治疗儿童哮喘急性发作具有较好的疗效和安全性,其作用与降低血清MMP-9与TIMP-1比值,抑制慢性气道炎症、气道重塑和气道纤维化密切相关。
Objective： To explore the clinical effect and influence of montelukast on matrix metalloproteinase-9 （MMP-9） and tissue inhibitor of metalloproteinase-1 （TIMP-1） in asthma children. Methods： Eighty asthma children during acute attack were divided into a montelukast group and a control group randomly. All the children received fundamental treatment such as anti-infection, spasmolysis and antiasthma. And the children of the montelukast group received montelukast （5 mg per day） for 12 weeks. Results： The plasma level of MMP-9 and MMP-9/TIMP-1 ratio were decreased, while TIMP-1 level was increased significantly after 12 weeks＇ treatment （P〈0.05）. The differences were significant between the two groups （ P 〈 0.05 ）. The total clinic effective rate of the montelukast group was significantly higher than that of control group （X2 = 4.11, P〈0.05 ）. No obvious adverse reaction was found during therapy period of the two groups. Conclusions： Treating asthma with montelukast shows a good curative effect and safety. Its mechanism may be downregulating MMP-9/TIMP-1 ratio, suppressing the process of airway chronic inflammation, remodeling and fibrosis.
出处
《儿科药学杂志》
CAS
2014年第3期21-23,共3页
Journal of Pediatric Pharmacy
关键词
哮喘
孟鲁司特
金属蛋白酶-9
金属蛋白酶抑制剂-1
Asthma
Montelukast
Matrix metalloproteinase-9
Tissue inhibitor of metalloproteinase-1
